Ondine Biomedical Inc.

Transaction in Own Shares • Feb 21, 2022

National Storage Mechanism | Additional information

RNS Number : 2035C

Ondine Biomedical Inc.

21 February 2022

21 February 2022

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Grant of Options and PDMR Dealing

Ondine Biomedical Inc. (AIM: OBI), announces the grant of options to acquire, in aggregate, up to 600,000 common shares (the "Options").

Options to acquire up to 600,000 shares have been granted pursuing to the Ondine Company Share Option Plan. The Options will vest evenly over four years, starting immediately and fully vesting on 4 February 2026. The Options will be exercisable throughout the vesting period and until the 4 February 2027, at a price of £0.54 per new ordinary share.

The Options has been granted to Charles Young, the Company's Vice President Sales & Marketing, North America, and to William Kanz, Vice President Engineering, and the notification below, made in accordance with the UK Market Abuse Regulation, provides further details in this regard. 

PDMR	Position	Number of Shares Under Option	Exercise Price	Vesting Date	Expiry Date
Charles Young	Vice President Sales & Marketing, North America	400,000	£0.54	Fully vested February 4, 2026	February 4, 2027
William Kanz	Vice President Engineering	200,000	£0.54	Fully vested February 4, 2026	February 4, 2027

Following the grant of the Options, the Company has options outstanding over a total of 8,098,000 shares, which represent approximately 4.2% of the Company's existing issued ordinary share capital.

For further Information, contact:

Ondine Biomedical Inc.           

Carolyn Cross, CEO

Telephone: +1 604 669 0555

Arden Partners plc      

Nominated Adviser and Broker

Ruari McGirr / Antonio Bossi     

Telephone: +44 (0)20 7614 5900

Media Contact:

Simon Vane Percy

Telephone: +44 (0)7710005910

Email: [email protected] / [email protected]

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Charles Young

2

Reason for the notification

a)

Position/status

Vice President Sales & Marketing, North America

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ondine Biomedical Inc.

b)

LEI

9845005B69E07CGF4A56 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Stock Options for Ordinary Shares

b)

Nature of the transaction

Grant of share option under the Ondine Biomedical Company Share Option Plan

c)

Price(s) and volume(s)

Price(s)	Volume(s)
nil	400,000

d)

Aggregated information

- Aggregated volume

- Price

N/A - single transaction

e)

Date of the transaction

February 17, 2022

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

William Kanz

2

Reason for the notification

a)

Position/status

Vice President Engineering

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ondine Biomedical Inc.

b)

LEI

9845005B69E07CGF4A56 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Stock Options for Ordinary Shares

b)

Nature of the transaction

Grant of share option under the Ondine Biomedical Company Share Option Plan

c)

Price(s) and volume(s)

Price(s)	Volume(s)
nil	200,000

d)

Aggregated information

- Aggregated volume

- Price

N/A - single transaction

e)

Date of the transaction

February 17, 2022

f)

Place of the transaction

Outside of a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHURRNRUBUUUAR